News for Monopar Therapeutics Inc. (MNPR)

Monopar Therapeutics (MNPR) has unveiled promising data regarding its drug candidate, ALXN1840, at the 2025 European Association for the Study of the Liver Inte

WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ( MNPR), a clinical-stage biopharmaceutical company focused on developing innovativ

Monopar Therapeutics (MNPR) presents promising ALXN1840 data for Wilson disease at EASL 2025. Clinical trials show sustained symptom improvements and su

**media[616953]**

We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where Monopar Therapeutics Inc.

We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where Monopar Therapeutics Inc. (NASDAQ:MNPR) stands against other healthcare stocks that are surging in 2025. After lagging behind the broader market in 2024, many healthcare stocks are making a […]

WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ( MNPR), a clinical-stage biopharmaceutical company focused on developing innovat

Monopar Therapeutics (MNPR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

On December 31, 2024, RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio) executed a significant transaction by acquiring an additional 108,909 shares of Monopar Th

From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology company has made a remarkable comeback.

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Monopar Therapeutics Inc (NASDAQ:MNPR) stands ...

Monopar Therapeutics Stock Hits 52-Week High at $38.91

Learn about the promising Monopar Therapeutics Inc. MNPR-101 treatment targeting solid tumors and how it aims to reduce investor risk. Click for more on NMPR.

Stocks Analysis by Professor Ari Zoldan covering: US Small Cap 2000, Alexion Pharmaceuticals Inc, AstraZeneca PLC ADR, Monopar Therapeutics Inc. Read Professor Ari Zoldan's latest article on Investing.com

**media[497847]**

Monopar Therapeutics sets stock and warrant offering prices

Monopar Therapeutics (MNPR) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ( MNPR), a clinical-stage biotechnology company focused on developing innovative t

Shares of Deckers Outdoor Corporation DECK rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial r...